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While children approaching end-stage kidney disease (esKD) are considered at risk of uremic anorexia 
and underweight they are also exposed to the global obesity epidemic. We sought to investigate the 
variation of nutritional status in children undergoing chronic peritoneal dialysis (CpD) around the globe. 
the distribution and course of body mass index (BMI) standard deviation score over time was examined 
prospectively in 1001 children and adolescents from 35 countries starting CPD who were followed in 
the International pediatric pD Network (IppN) Registry. the overall prevalence of underweight, and 
1center for Pediatrics and Adolescent Medicine, Heidelberg, Germany. 2institute of Medical Biometry and 
informatics, University of Heidelberg, Heidelberg, Germany. 3Medical University of Gdansk, Department of 
Pediatrics, Nephrology and Hypertension, Gdańsk, Poland. 4nemours/A.i. duPont Hospital for children, Wilmington, 
De, USA. 5children’s Hospital of fundan University, Shanghai, china. 6Great Ormond Street Hospital, London, 
United Kingdom. 7Department of Pediatric Nephrology, National Kidney and Transplant Institute, Quezon City, 
Philippines. 8Dr. Behcet Uz Children Research and Educational Hospital, Izmir, Turkey. 9iran University of Medical 
Sciences, tehran, iran. 10nationwide children’s Hospital, columbus, OH, USA. 11carrahpasa School of Medicine, 
istanbul, turkey. 12University Hospital Motol, Prague, Czech Republic. 13Seattle children’s Hospital, Seattle, WA, 
USA. 14S.e.n.n.i.A.D, Montevideo, Uruguay. 15Department of nephrology, Starship children’s Hospital, Auckland, 
new Zealand. 16HUcH Hospital for children and Adolescents, Helsinki, finland. 17istanbul University, istanbul faculty 
of Medicine, istanbul, turkey. 18Service de néphrologie Pédiatrique, Hôpital femme Mère enfant, Hospices civils 
de Lyon, Lyon, france. 19children’s Memorial Health institute, Warsaw, Poland. 20Pediatric nephrology, Dialysis and 
Transplantation Unit Fondazione IRCCS Ca’ Granda Osp. Maggiore Policlinico, Milan, Italy. 21Jagellonian University 
Medical college, Kraków, Poland. 22Semmelweis University, Budapest, Hungary. 23Dubai Hospital, Dubai, United 
Arab emirates. 24NRS Medical College & Hospital, Kolkata, India. 25Children Hospital, affiliate of Vilnius University 
Hospital Santaros Klinikos, Vilnius, Lithuania. 26Lucile Packard children’s Hospital at Stanford, Palo Alto, USA. 
27children’s Medical center Dallas, Dallas, tx, USA. 28Department of Pediatric Gastroenterology, nephrology and 
Metabolism, charité, Berlin, Germany. 29erciyes University, Kayseri, turkey. 30Hospital Sotero del Rio, Santiago, 
chile. 31CHU Arnaud de Villeneuve, Université de Montpellier, Montpellier, France. 32Barnkliniken, Lund, Sweden. 
33children’s Mercy Hospital, Kansas city, MO, USA. *A comprehensive list of consortium members appears at the 
end of the paper. correspondence and requests for materials should be addressed to f.S. (email: franz.schaefer@
med.uni-heidelberg.de)
Received: 27 June 2018
Accepted: 26 November 2018
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:4886  | https://doi.org/10.1038/s41598-018-36975-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
overweight/obesity at start of CPD was 8.9% and 19.7%, respectively. Underweight was most prevalent 
in South and Southeast Asia (20%), Central Europe (16.7%) and Turkey (15.2%), whereas overweight 
and obesity were most common in the Middle East (40%) and the US (33%). BMI SDS at PD initiation 
was associated positively with current eGFR and gastrostomy feeding prior to pD start. over the course 
of pD BMI sDs tended to increase on CpD in underweight and normal weight children, whereas it 
decreased in initially overweight patients. In infancy, mortality risk was amplified by obesity, whereas 
in older children mortality was markedly increased in association with underweight. Both underweight 
and overweight are prevalent in pediatric esKD, with the prevalence varying across the globe. Late 
dialysis start is associated with underweight, while enteral feeding can lead to obesity. Nutritional 
abnormalities tend to attenuate with time on dialysis. Mortality risk appears increased with obesity in 
infants and with underweight in older children.
The nutritional status is a principal concern when caring for children undergoing chronic peritoneal dialysis 
(CPD). While early studies revealed providing sufficient nutrition was essential for adequate growth in this popu-
lation, advances in enteral feeding practices have enabled the elimination of underweight but have not improved 
linear growth as much as expected1–3. Recent concerns have emerged on the potential for adverse effects of exces-
sive caloric intake in patients who receive supplemental feeding1–3.
The majority of published studies assessing the nutritional status of dialyzed children were performed at 
highly specialized pediatric dialysis units in North America and Western Europe. In contrast, on a global scale 
the risk of nutritional abnormalities in individual regions and countries is likely to be affected by a range of medi-
cal and non-medical factors including the patient case-mix regarding age, underlying disease and co-morbidities, 
national economic strength and healthcare expenditure, cultural acceptability of dietary and feeding prescrip-
tions, availability of special formula diets and enteral feeding equipment, and differences in local, national or 
regional nutritional recommendations4.
The International Pediatric Peritoneal Dialysis Network (IPPN) has been collecting comprehensive clinical 
and laboratory data in a standardized manner from children undergoing CPD worldwide since 2007. Since these 
data include detailed anthropometric measures, feeding prescriptions and outcome measures, it provides an 
opportunity to address the global demographics of nutritional abnormalities in children receiving CPD.
The objective of this study was to examine and follow prospectively the nutritional status of 1,001 children 
commencing CPD around the globe, analyze factors associated with the nutritional status at the start and during 
the course of dialysis, and to analyze the impact of nutritional abnormalities on patient survival.
Methods
Data collection. The IPPN Registry was established in 2007 and currently collects comprehensive clinical 
and laboratory information from children undergoing CPD at 95 pediatric dialysis centers in 37 countries around 
the globe. Patient status is updated every 6 months via an Internet-based web platform (www.pedpd.org). The 
complete list of data items collected has been published previously2,4. Data is automatically checked for plausibil-
ity and completeness. Data protection is ensured by pseudonymized data input. The study is performed in accord-
ance with the relevant medical association’s professional codes of conduct with the Declaration of Helsinki from 
2008. Approval for the registry project was obtained from The Children’s Mercy Hospital Pediatric Institutional 
Review Board, Kansas City, USA and local Institutional Review Boards or ethical committees. Informed consent 
was obtained from the patients and/or their legal guardians as required by local review boards.
Calculation of BMI sDs and eGFR. Body Mass Index (BMI), i.e. weight/height2 (kg/m2), was normal-
ized to standard deviation scores (SDS) according to height age, utilizing the WHO (2006) and CDC (2000) 
standards for children aged younger and older than 5 years, respectively (see www.who.int/childgrowth/en/)5,6. 
Normalization to height age, i.e. the chronological age of a child with the same height growing at the 50th height 
percentile, was made to adjust for the high prevalence of growth failure in the cohort7. BMI SDS values were used 
to categorize patients into three BMI groups: underweight (<2.5th percentile, i.e. <−2 SDS), normal (2.5th to 85th 
percentile, i.e. −2 to 1.036 SDS), overweight (>85th −95th percentile, i.e. >1.036 to 1.645 SDS), and obesity (>95th 
percentile, i.e. >1.645 SDS). The Schwartz bedside formula was used to estimate GFR at initiation of CPD8.
statistics. Data collection was complete for all observations except residual urine output (7.6% missing data), 
daily ultrafiltration rate (5.2%), eGFR (1.2%), total PD fluid turnover and dialytic glucose exposure (0.8%), PD 
modality (0.5%), serum bicarbonate (0.3%), serum albumin (0.2%), and estimated dry weight (0.2%). Multiple 
imputation by chained equations was conducted to replace these missing values9. All analyses were performed 
using the imputed dataset. Additionally, sensitivity analyses were performed using only cases with complete data 
sets.
ANOVA or Kruskal-Wallis tests were conducted to compare differences between BMI groups. Differences in 
proportions were assessed using Chi2 tests. Linear mixed modeling was used to identify factors affecting BMI SDS 
at baseline and during follow-up. The initial cross sectional model included age, sex, eGFR, gross national income 
(GNI), renal diagnosis, presence of comorbidities, ethnicity, urine output, nutritional support (oral caloric sup-
plements, nasogastric tube (NGT) and gastrostomy feeding), and growth hormone use as independent variables. 
The region of residence was accounted for as random intercept. For the longitudinal analysis, the change in BMI 
SDS between two observations, projected to 12 months, was used as the dependent variable and region and 
patients were used as nested random effects. Potential covariates included in the initial model were age at baseline, 
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sex, presence of comorbidities, renal diagnosis, GNI and the time-varying variables BMI SDS, height SDS, eGFR, 
% deviation from estimated dry weight, PD modality, duration of PD, serum albumin, serum bicarbonate, total 
PD fluid volume, urine output, ultrafiltration, growth hormone use, nutritional support, glucose exposure, bio-
compatible PD fluid use, and amino acid PD fluid use. A stepwise variable selection procedure was applied to 
identify the relevant covariates for the cross sectional model as well as for the longitudinal model, using p = 0.2 
as a cutoff criterion for model entry.
Kaplan–Meier analysis with log-rank testing was used to assess differences in patient survival. Cox propor-
tional hazard modeling with time dependent covariates and interaction term was applied to identify risk factors 
of death on dialysis.
Data were analyzed using SAS, version 9.3 (SAS Institute, Inc., Cary, NC), and R, version 3.1.110.
Results
study population. All children and adolescents enrolled in the IPPN registry with initiation of CPD 
between March 2007 and December 2014 were analyzed for this study. Five patients with syndromic and meta-
bolic disorders associated with intrinsic abnormalities of growth and body composition were excluded from the 
analysis. The final dataset comprised a total of 1,001 incident patients from 85 nephrology centers in 35 countries. 
Children originated from Western Europe (n = 300), Central Europe (n = 120), Turkey (n = 105), the Middle 
East (n = 15), China and Hong Kong (n = 77), Korea (n = 24), India and South East Asia (n = 30), New Zealand 
(n = 18), USA (n = 97), Canada (n = 13) and Latin America (n = 202). One or more comorbidities were reported 
in 369 patients (35.6%); these included mainly defined syndromic disorders (n = 107), impaired cognitive devel-
opment (n = 119), cardiac (n = 130) and pulmonary abnormalities (n = 52).
Of the 1,001 patients, 702 (70%) patients had at least two BMI records available. Median follow-up time was 
14.5 (IQR 17.8) months. Altogether, the data set contained 2,931 follow-up entries.
Nutritional status at dialysis initiation. The overall prevalence of underweight, normal weight and over-
weight/obesity at the start of CPD was 8.9%, 71.4%, and 19.7%, respectively. The detailed patient characteris-
tics according to nutritional status at dialysis entry are shown in Table 1. Overweight/obese children originated 
from countries with higher GNI per capita, had higher eGFR at CPD initiation and were more growth retarded. 
Gastrostomy feeding was performed in almost 17% of the overweight children as compared to 8% and 6% in the 
normal and low BMI groups (p < 0.001 for comparison of gastrostomy feeding between overweight and normal, 
as well as between overweight and low BMI). Children starting PD with underweight more often received amino 
acid PD fluid than children without underweight (p = 0.013).
The distribution of underweight, normal weight, and overweight/obese patients according to geographical 
region is depicted in Fig. 1. The prevalence of nutritional abnormalities varied significantly across world regions. 
Underweight was most prevalent in South and Southeast Asia (20%), followed by Central Europe (16.7%) and 
Turkey (15.2%), whereas overweight and obesity were most common in the Middle East (40%) and the US (33%).
The prevalence of underweight was highest in the first year of life (14.2%), decreasing to 6.5%, 9.4% and 
7.7% in children aged 1–<6, 6–12 and older than 12 years, respectively (Fig. S1 in supplement). The preva-
lence of underweight was correlated with the eGFR at initiation of PD, increasing from 5.3% at eGFR 9–12 ml/
min/1.73 m2 to 11% at eGFR < 6 ml/min/1.73 m2 (p = 0.03) (see also Fig. S2). The prevalence of obesity was higher 
in the younger children than in adolescents, whereas the prevalence of being overweight was largely independent 
of age (see Fig. S1).
By multivariate analysis, BMI SDS at dialysis initiation was positively predicted by eGFR and the use of gas-
trostomy feeding and negatively predicted by the presence of comorbidities, whereas age, sex, ethnicity, GNI, 
renal diagnosis, and growth hormone use were not predictive (Table S1).
enteral feeding practices. To further explore and compare regional characteristics in nutrition manage-
ment, enteral feeding patterns were investigated. Enteral (NGT or gastrostomy) feeding was used at baseline in 
57.4%, 32.9%, 5.6%, and 2.3% of children <1, 1–<6, 6–12 and >12 years, respectively (p < 0.001). The variation 
of feeding practices varied markedly by region (Fig. 2). Enteral feeding was rarely applied in Central Europe, 
Turkey, India, South East Asia, and China. Gastrostomy usage was confined to North America, Western Europe, 
Korea and New Zealand. Among the 386 children <6 years, 166 were followed for at least 12 months on dialysis. 
The fraction of children with enteral tube feeding was 38% at baseline and 41% at follow up (ns).
Changes in nutritional status with time on CpD. Changes in BMI SDS were analyzed using 702 patients 
with at least two available BMI records. During a median follow-up time of 15 (interquartile range 18) months, 
BMI SDS tended to increase on CPD in both underweight and normal weight children, whereas it decreased in 
the overweight patients (Fig. 3). Out of 74 underweight children at the start of CPD, 51.4% were non-underweight 
at last observation; among 125 overweight/obese children at CPD initiation, 36.0% achieved a normal BMI at 
follow-up.
Gastrostomy feeding was associated with an increase in BMI SDS during follow-up (Table 2). Additional 
factors independently associated with a positive change in BMI SDS included a lower BMI SDS and higher height 
SDS, higher serum albumin and the diagnosis of CAKUT. In contrast, greater fluid overload (expressed as % devi-
ation from estimated dry weight) was predictive of a negative change in BMI SDS during follow-up.
Nutrition and mortality. A total of 54 children died during the observation period. The most common 
causes of death were non-PD related infections (39%), followed by congestive heart failure (17%), PD-related 
infections (7%) and malignances (7%). The 1-, 2- and 4-year survival rates were 91%, 84%, and 74% in patients 
who were underweight at last observation, as compared to 95%, 93% and 89% in those with final higher BMI SDS 
values (p = 0.03) (Fig. 4). Cox proportional hazard analysis identified the presence of comorbidities and younger 
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age as risk factors for death on dialysis (Table 3). Whereas BMI SDS per se was not predictive, the interaction 
term of BMI SDS and age affected the risk of death at borderline significance (p = 0.06). To further illustrate the 
interaction of age and BMI SDS with respect to mortality risk on dialysis, we modeled the hazard ratio of death 
by age for patients with a BMI SDS of −2, 0, and 2 (Fig. 5). While the globally increased risk of death of children 
younger than 5 years of age is more marked in obese children, at older age underweight children appear at higher 
risk of death than obese ones.
Total population BMI < 2.5th percentile BMI 2.5th–85th pct BMI > 85th pct P
N = 1001 n = 89 n = 715 n = 197
Country GNI per capita (1000$) 27.1 ± 13.6 24.0 ± 13.2 27.0 ± 13.4 28.6 ± 14.5 0.03
Age (yrs) 8.5 ± 5.8 7.7 ± 5.9 8.7 ± 5.8 8.1 ± 5.8 0.18
Male gender 550 (55%) 50 (56.2%) 388 (54.3%) 112 (56.9%) 0.79
Renal diagnosis 0.24
   CAKUT 424 (42.4%) 44 (49.4%) 291 (40.7%) 89 (45.2%)
   Glomerulopathy 388 (38.8%) 30 (33.7%) 292 (40.8%) 66 (33.5%)
   Other 189 (18.9%) 15 (16.9%) 132 (18.5%) 42 (21.3%)
Comorbidities 355 (35.5%) 38 (42.7%) 250 (35.0%) 67 (34.0%) 0.32
eGFR at PD start (ml/min/1.73 m2) 8.0 (5.3) 7.3 (5.1) 7.9 (5.2) 8.8 (5.6) 0.01
Urine output (L/m2/d) 0.61 (0.94) 0.53 (0.85) 0.63 (0.93) 0.56 (1.05) 0.80
PD modality 0.51
   CAPD 222 (22.6%) 23 (25.8%) 156 (21.8%) 43 (21.8%)
   APD 759 (77.4%) 60 (67.4%) 547 (76.5%) 152 (77.2%)
   Other 13 (1.3%) 6 (6.7%) 6 (0.8%) 1 (0.5%)
Biocompatible PD fluid use 428 (42.8%) 33 (37%) 316 (44.2%) 79 (40.1%) 0.31
Height SDS −1.9 ± 1.7 −1.6 ± 2.1 −1.8 ± 1.6 −2.3 ± 1.8 <0.001
Nutritional supplementation
None 595 (59.4%) 54 (60.7%) 428 (59.9%) 113 (57.4%) 0.01
Oral nutritional supplements 218 (21.8%) 24 (27%) 160 (22.4%) 34 (17.3%)
NG tube 92 (9.2%) 6 (6.7%) 69 (9.6%) 17 (8.6%)
Gastrostomy 96 (9.6%) 5 (5.6%) 58 (8.1%) 33 (16.7%)
Amino acid PD fluid use 12 (1.2%) 4 (4.5%) 5 (0.6%) 3 (1.5%) 0.01
Growth hormone use 64 (6.4%) 3 (3.4%) 50 (7.0%) 11 (5.6%) 0.37
Hemoglobin (g/L) 10.8 ± 1.9 11.0 ± 2.1 10.8 ± 1.9 10.8 ± 1.8 0.61
Serum albumin (g/l) 35.8 ± 6.9 36.2 ± 5.4 35.6 ± 7.2 36.2 ± 6.6 0.512
Blood urea (mg/dl) 96 (63) 93 (64) 97 (63) 93 (62) 0.52
Serum bicarbonate (mM) 23.9 ± 4.3 23.7 ± 4.1 23.9 ± 4.2 24.2 ± 4.7 0.63
Serum phosphorus (mM) 1.8 ± 0.6 1.8 ± 0.6 1.8 ± 0.6 1.7 ± 0.6 0.20
Table 1. Patient and treatment baseline characteristics. Data are expressed as n (%), median (IQR) or 
mean ± SD.
Figure 1. Regional variation of nutritional status at start of CPD, sorted by decreasing fraction of patients with 
BMI within normal range.
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Figure 2. Regional differences in supplementary feeding practices in 386 children <6 years, sorted by 
increasing fraction of patients without enteral feeding.
Figure 3. Course of BMI SDS according to nutritional status at start of PD (green: normal BMI, blue: 
overweight/obese, red: underweight). Regression lines are based on a mixed model predicting BMI SDS from 
duration of PD, nutritional status at start of PD and their interaction.
Parameter Estimate (SE) P
Intercept −0.056 (0.259) 0.89
Duration of PD (years) −0.060 (0.036) 0.09
Diagnosis (reference: CAKUT)
Glomerulopathy −0.229 (0.089) 0.01
Other −0.364 (0.110) 0.001
BMI SDS −0.456 (0.026) <0.001
Height SDS 0.113 (0.025) <0.001
% deviation from estimated dry weight −0.040 (0.014) 0.01
Serum albumin (g/L) 0.015 (0.006) 0.02
Nutritional supplementation (reference: none)
Oral −0.195 (0.090) 0.03
NGT 0.122 (0.133) 0.36
Gastrostomy 0.633 (0.132) <0.001
Table 2. Factors predicting prospective annualized change in BMI SDS. Positive change means BMI SDS 
increase (702 patients, 1930 differences in BMI SDS).
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Discussion
At variance with historical epidemiological studies on nutrition in children with CKD, which focused mainly on 
uremic underweight, this study highlights a changing trend of the nutritional status in pediatric end stage kid-
ney disease (ESKD). Both underweight and overweight/obesity were common. Using the 2.5th and the 85th BMI 
percentiles as cutoffs for underweight and overweight/obesity respectively, 28.6% of patients receiving CPD, as 
compared to an expected 17.5%, exhibited an abnormal body composition.
A relatively low rate of underweight, but an increased prevalence of overweight and obesity was recently also 
observed in North American CKD cohorts11,12 and in European children undergoing dialysis13. While it is tempt-
ing to merely attribute this trend to the global childhood obesity epidemic, the comprehensive and worldwide 
Figure 4. Survival of patients with underweight (BMI < 2.5th percentile) (red) and without underweight 
(BMI > 2.5th percentile) (green) at last observation (log-rank test: p = 0.03).
Estimate (SE) Hazard ratio
95% Confidence 
Interval P
Comorbidity 0.836 (0.279) 2.307 [1.336, 3.987] 0.001
Age −0.102 (0.028) 0.903 [0.856, 0.954] <0.001
BMI SDS 0.136 (0.123) 1.145 [0.900, 1.457] 0.27
BMI SDS * Age −0.028 (0.015) 0.973 [0.945, 1.002] 0.06
Table 3. Risk factors for death on CPD.
Figure 5. Hazard ratios of death according to age and BMI SDS (reference: age = 0, BMI SDS = 0) for a patient 
with no comorbidities, based on Cox regression with time dependent variables age, BMI SDS, presence of 
comorbidities and the interaction of bmi sds and age.
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data collection in the IPPN Registry allowed us to dissect in detail and on a global scale, the impact of macro-
economic factors, patient characteristics, and pediatric CKD and dialysis management practices on nutritional 
outcome.
The regional breakdown and comparison with the general childhood population prevalence data revealed that 
overweight and obesity in the CPD patients was indeed most prevalent in children and adolescents from the US 
and the Middle East, and comparable to the national prevalence rates in these countries which show the highest 
prevalence of childhood obesity worldwide14. On the other hand, when relating the observed obesity rates to the 
current prevalences in the general pediatric populations of the respective regions, obesity was slightly less com-
mon in patients from Western Europe, but was substantially more frequent in children from South and South East 
Asia14. The latter finding might be explained in part by overrepresentation of families from upper socioeconomic 
strata to whom chronic dialysis is affordable. Noteworthy also was the finding that whereas gross national income 
was positively correlated with overweight/obesity prevalence by univariate analysis, it was not included in the 
multivariate models predicting BMI at initiation of dialysis and during follow-up. This suggests that the observed 
regional differences can be explained in large part by the medical factors included in the multivariate analysis.
Two factors were consistently associated with BMI SDS at the time of PD initiation: the most current eGFR 
and the use of gastrostomy feeding prior to PD start. The positive association with eGFR is compatible with the 
notion that the risk of uremic underweight increases as residual kidney function declines in the late pre-dialytic 
phase. Centers in countries where late referral to pediatric nephrology care is common may be more likely to 
start PD in underweight patients with little residual kidney function. In the case of children for whom PD is to be 
started electively, our findings add a nutritional perspective to the list of factors to be considered when determin-
ing the optimal timing of PD initiation.
The most important single factor associated with higher BMI SDS both at PD start and during follow-up was 
the presence of a gastrostomy. In the multivariate longitudinal analysis, gastrostomy feeding accounted for an 
increase in BMI by almost two standard deviations per three years of treatment. Accordingly, gastrostomy feeding 
was almost three times more common among overweight and obese as compared to underweight patients. These 
findings confirm and extend a previous IPPN study in young infants, which identified PEG feeding as a risk factor 
for obesity2. Since the use of gastrostomy feeding was found to be largely restricted to high-income countries, 
enteral feeding via gastrostomy appears to be the most important factor underlying the observed link between 
Gross National Income and higher BMI.
An unexpected observation was the fact that obese - but not underweight - patients were significantly shorter 
than patients with normal nutritional status at the initiation of renal replacement therapy. This finding, which is 
in keeping with recent findings in the ESPN/ERA-EDTA registry13 and previous reports15, may reflect previous 
frustraneous interventions to correct growth failure by hypercaloric feeding.
An important and reassuring finding from the longitudinal analysis is the observation that nutritional abnor-
malities, both underweight and overweight/obesity, tend to level off over the course of dialysis. The prevailing 
BMI SDS was a highly significant inverse predictor of the subsequent change in BMI SDS in the longitudinal 
model. This ‘funneling’ of the nutritional status is likely to be a consequence of regular nutritional monitoring 
and dietary advice. Direct effects of dialysis such as control of uremia, correction of acidosis and dialytic glucose 
resorption probably play a role in the correction of underweight, but these factors were not included as signifi-
cant predictors of prospective BMI SDS change in the overall model since they are less likely to increase BMI in 
patients with normal nutritional status.
Remarkably, patients with congenital kidney malformation disorders (CAKUT) were more likely to gain BMI 
SDS over the course of dialysis than patients with other underlying renal diseases. Since CAKUT is the most 
common renal diagnosis in infants with ESKD and was slightly more common among initially underweight 
patients, we speculate that catch-up weight gain due to enteral feeding was more common in this patient group. 
In addition, as CAKUT patients are often polyuric even at commencement of dialysis, part of the observed BMI 
gain may be explained by relative fluid gain to the gradual loss of diuresis with time on PD.
The estimated fractional deviation from dry weight was associated with a subsequent negative change in BMI 
SDS, possibly reflecting the impact of early fluid imbalances (e.g. hypervolemia) and their correction with time 
on CPD. When patients with substantial fluid overload have their body weight decreased because of improved 
fluid management, this will be recorded as a negative change in BMI, illustrating the limitation of BMI SDS as a 
measure of nutritional status.
Nutritional status is a well recognized, major global determinant of mortality in the general adult and pedi-
atric population, as well as in adults and children with ESKD16–18. The overall patient survival observed in this 
global sample of children and adolescents starting CPD (91% at 2 years) was not dissimilar from survival rates 
noted in North American and European registry cohorts19–21. Wong et al., in the only other large study examining 
BMI and mortality in pediatric ESRD, demonstrated a U-shaped association between the risk of death and BMI 
SDS, with both extremes of BMI associated with increased mortality19. An increased death risk was also observed 
in children with a hematological malignancy who were either underweight or obese22. In the present study, 
underweight patients were twice as likely to die on dialysis as non-underweight children by univariate Kaplan 
Meier survival analysis, whereas obesity did not affect the risk of death. On the other hand, when accounting for 
age and the presence of comorbidities in a Cox regression model, although BMI SDS did not predict the risk of 
death, age and BMI SDS showed an interactive effect; specifically, an increased infant mortality was amplified by 
obesity, whereas mortality in older children and adolescents was markedly increased by underweight. Hence, our 
findings are compatible with an age-dependent impact of the extremes of body composition on patient survival. 
We hypothesize that the morbid obesity generated in a subset of young infants by enteral feeding may, in fact, 
put these patients at increased risk of death. Possible underlying causes of this risk association might include 
enhanced cardiovascular risk due to the difficulty of assessing fluid status in obese infants and the susceptibility 
of obese subjects to severe outcomes following viral respiratory infections23.
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While the strength of our study relates to the robust set of data available from a large group of pediatric CPD 
patients, several limitations of our study should be mentioned. Although BMI is a generally accepted method to 
assess nutritional status in healthy children24–26, it is an imperfect measure of body composition. This is particu-
larly true in pediatric dialysis patients as it does not account for abnormalities of fluid status and is impacted by 
abnormal body height. While the latter issue was accounted for by calculation of BMI SDS for height age27,28, a 
more refined auxological assessment was not possible in this global registry. Another important limitation of our 
study was the lack of detailed data on dietary prescriptions and caloric intake, which would be difficult to obtain 
due to complexity of data collection in such a large and diverse cohort of patients.
In summary, this longitudinal assessment of 1001 children from 35 countries commencing CPD demon-
strates that both underweight and obesity are observed at increased frequency in pediatric ESRD. The prevalence 
of both abnormalities varies substantially across the globe. Delayed start of dialysis is a risk factor for under-
weight whereas enteral tube feeding, while protecting from underweight, increases the risk of developing obesity. 
Nutritional abnormalities tend to attenuate with time on dialysis.
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